Business
Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting
Aadi initiates Phase 2 trial investigating the combination of nab-sirolimus with letrozole for the treatment of advanced or recurrent endometrioid-type
About this update from Whitehawk Therapeutics, Inc.
[{"type":"text","content":"Aadi initiates Phase 2 trial investigating the combination of nab-sirolimus with letrozole for the treatment of advanced or recurrent endometrioid-type endometrial cancer (EEC)\nLOS ANGELES, Oct. 19, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced e-poster presentations at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting, taking place November 5-7, 2023, in Seoul, Korea.\nAbstract and e-poster presentation details are below:\nTitle: \"A phase 2, open-label, single-arm, prospective, multi-center study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer\"Session Title: e-posterDate/Time: November 5-7, 2023Authors: Lauren E. Dockery, MD, MS; Anna Priebe, MD; Linda Duska, MD, MPH; Angela K. Green, MD; Cara Mathews, MD; Fernanda Musa, MD; David O'Malley, MD; Allison Puechl, MD; Li Ding, MS, MA; Anita N. Schmid, PhD; Willis H. Navarro, MD; Brian Slomovitz, MD; Kathleen Moore, MD\nAbstract highlights:\nThis is a Phase 2 open-label, multi-institutional study to evaluate the efficacy and safety of nab-sirolimus and letrozole in patients with advanced or recurrent endometrioid endometrial carcinoma, exploring the potential for this combination to produce additive anti-tumor activity in patients with endometrioid-type endometrial carcinoma (EEC)Dysregulation of mTOR signaling is implicated in the pathology of EEC, in which >80% harbor PTEN or PI3K/AKT/mTOR pathway alterationsPrior clinical studies with mTOR inhibitors and letrozole in endometrial cancer patients have yielded promising resultsAlternative treatment options for advanced or recurrent endometrioid-type endometrial carcinoma (EEC) remain necessary despite recent pivotal data demonstrating improved outcomes with immunotherapy plus chemotherapyIn preclinical models, intravenous nab-sirolimus demonstrates significantly higher tumor growth inhibition, intra-tumoral drug accumulation, and greater mTOR target suppression compared with oral inhibitorsAn encore presentation titled, \"Phase 2, Multicenter, Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 (PRECISION1)\" will be displa...